MX2010010000A - Derivados de 2-trifluorometilnicotinamida como agentes para aumentar el colesterol de lipoproteinas de alta densidad. - Google Patents

Derivados de 2-trifluorometilnicotinamida como agentes para aumentar el colesterol de lipoproteinas de alta densidad.

Info

Publication number
MX2010010000A
MX2010010000A MX2010010000A MX2010010000A MX2010010000A MX 2010010000 A MX2010010000 A MX 2010010000A MX 2010010000 A MX2010010000 A MX 2010010000A MX 2010010000 A MX2010010000 A MX 2010010000A MX 2010010000 A MX2010010000 A MX 2010010000A
Authority
MX
Mexico
Prior art keywords
hdl
trifluoromethylnicotinamide
derivatives
raising agents
cholesterol raising
Prior art date
Application number
MX2010010000A
Other languages
English (en)
Inventor
Paul Hebeisen
Pius Waldmeier
Stephan Roever
Constantinos G Panousis
Matthew Wright
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2010010000A publication Critical patent/MX2010010000A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La presente invención, se refiere a compuestos de la fórmula (I) en donde R1 a R8 son tal y como se definen en la descripción y las reivindicaciones para la preparación de medicamentos para el tratamiento y/o profilaxis de enfermedades que pueden tratarse con agentes para aumentar el colesterol HDL, tal como preferiblemente dislipemia.
MX2010010000A 2008-03-31 2009-03-23 Derivados de 2-trifluorometilnicotinamida como agentes para aumentar el colesterol de lipoproteinas de alta densidad. MX2010010000A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08153792 2008-03-31
PCT/EP2009/053343 WO2009121740A1 (en) 2008-03-31 2009-03-23 2-trifluoromethylnicotinamide derivatives as hdl-cholesterol raising agents

Publications (1)

Publication Number Publication Date
MX2010010000A true MX2010010000A (es) 2010-09-30

Family

ID=40601113

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010010000A MX2010010000A (es) 2008-03-31 2009-03-23 Derivados de 2-trifluorometilnicotinamida como agentes para aumentar el colesterol de lipoproteinas de alta densidad.

Country Status (14)

Country Link
US (1) US7897621B2 (es)
EP (1) EP2262770B1 (es)
JP (1) JP5442711B2 (es)
KR (1) KR101249668B1 (es)
CN (1) CN101981009B (es)
AR (1) AR071096A1 (es)
AU (1) AU2009231375A1 (es)
CA (1) CA2717537A1 (es)
ES (1) ES2391371T3 (es)
IL (1) IL208021A0 (es)
MX (1) MX2010010000A (es)
PE (1) PE20091826A1 (es)
TW (1) TW200944504A (es)
WO (1) WO2009121740A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2012DN03322A (es) * 2009-09-21 2015-10-23 Univ Vanderbilt
WO2012031817A1 (en) * 2010-09-09 2012-03-15 F. Hoffmann-La Roche Ag Determination of abca1 protein levels in cells
US8410107B2 (en) 2010-10-15 2013-04-02 Hoffmann-La Roche Inc. N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US8669254B2 (en) 2010-12-15 2014-03-11 Hoffman-La Roche Inc. Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0400208D0 (sv) 2004-02-02 2004-02-02 Astrazeneca Ab Chemical compounds
CA2602787C (en) 2005-04-06 2013-12-24 F. Hoffmann-La Roche Ag Pyridine-3-carboxamide derivatives as cb1 inverse agonists
US7629346B2 (en) 2006-06-19 2009-12-08 Hoffmann-La Roche Inc. Pyrazinecarboxamide derivatives as CB1 antagonists
US7781593B2 (en) 2006-09-14 2010-08-24 Hoffmann-La Roche Inc. 5-phenyl-nicotinamide derivatives
MX2009003316A (es) 2006-10-04 2009-04-09 Hoffmann La Roche Derivados de pirazina-2-carboxamida como moduladores receptores de cb2.
CA2664119A1 (en) 2006-10-04 2008-04-10 F. Hoffmann-La Roche Ag 3-pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as hdl-cholesterol raising agents

Also Published As

Publication number Publication date
EP2262770B1 (en) 2012-08-01
CN101981009B (zh) 2013-09-11
CA2717537A1 (en) 2009-10-08
PE20091826A1 (es) 2009-11-25
KR101249668B1 (ko) 2013-04-01
AU2009231375A1 (en) 2009-10-08
US7897621B2 (en) 2011-03-01
JP2011516444A (ja) 2011-05-26
KR20100117142A (ko) 2010-11-02
ES2391371T3 (es) 2012-11-23
AR071096A1 (es) 2010-05-26
TW200944504A (en) 2009-11-01
IL208021A0 (en) 2010-12-30
US20090247588A1 (en) 2009-10-01
WO2009121740A1 (en) 2009-10-08
JP5442711B2 (ja) 2014-03-12
CN101981009A (zh) 2011-02-23
EP2262770A1 (en) 2010-12-22

Similar Documents

Publication Publication Date Title
MX2015007556A (es) Derivados de manosa para tratar infecciones bacterianas.
MX2013003634A (es) Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales.
NZ597517A (en) 5-fluoropyrimidinone derivatives
PH12015500274A1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
IN2015DN01156A (es)
MX2013002660A (es) Heteroarilmetilamidas.
IN2012DN02081A (es)
MX343706B (es) Derivados heterocíclicos novedosos.
UA107783C2 (en) Isoindoline compounds for use in treating cancer
IN2012DN00624A (es)
TW201129565A (en) Tricyclic heterocyclic compounds, compositions and methods of use thereof
MX336381B (es) Boronatos como inhibidores de arginasa.
NZ628294A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
WO2009117676A3 (en) Novel piperidine derivatives as inhibitors of stearoyl-coa desaturase
IN2012DN00971A (es)
TN2012000042A1 (en) 5,6-bicyclic heteroaryl-containing urea compounds as kinase inhitors
MX2013004759A (es) Compuestos de oxima como agentes de elevacion de colesterol de lipoproteina de alta densidad (hdl).
MX342947B (es) Tratamiento de diabetes tipo 2.
NZ597570A (en) N1-acyl-5-fluoropyrimidinone derivatives
MX2014015884A (es) Compuestos antivirales.
NZ606730A (en) Methods for treating antipsychotic-induced weight gain
MY164998A (en) Isoquinolinone derivatives as nk3 antagonists
MY173636A (en) Method of treating dengue fever
MX2010009999A (es) Derivados de amidas del acido 3-trifluorometil-pirazina-2-carboxil ico como agentes para aumentar el colesterol de lipoproteinas de alta densidad.
IN2012DN00763A (es)

Legal Events

Date Code Title Description
FG Grant or registration